Astragaloside IV can block the combination of IDO1 and GBP1 to prevent the exhaustion of T cells caused by the extracellular secretion of IDO1, and further enhance the inhibitory effect of PD-1 inhibitors in lung cancer. This evidence concerns the gene PDCD1 and lung carcinoma.